Saturday, November 22, 2025 12:17:41 PM
Given that they said they have cash to get into 2027? Given they
just announced another what was it, $25 Mil to buy shares back?
Well it could te one of two things:
-the news of an increase in $s to buyback shares can lead to an
increase in the share price. So maybe the follow on announcement
of a major increase in the ATM (number of AUTHORIZED SHARES goes up)
amount that can be sold is supposed to offset the news of a buyback and even
make the shares cheaper to buy back. A WIN for the company IF they do a buyback.
And the ability to sell a lot more shares at an ATM can then do 2 things:
IF the share price runs up?
They can dilute at a much higher price (create fewer new shares to raise even more
cash)
and they can then raise the AUTHORIZED share count by up to $400 Mil worth of shares
sold. Could support a forward split.
I didn't realize till yesterday that the number of AUTHORIZED shares did NOT increase
in the same ratio of a split if one occurred. I could go into a deeper explanation, but
given this appears accurate? It appears that IF they are pondering a forward split for
instance, they likely need to increase the number of AUTHORIZED shares (which I believe
they just did with the upping to the $400 Mil mark).
Again, this is all premised on that I have been expecting them to due to the tight share count,
announce a forward split just to make more shares available to wall street. Like its been for
over a year now for those holding that long (or longer)? Have to wait and see where things go
vs what we anticipate based on our experiences/lessons learned.
Remains unchanged
Authorized shares when a stock aplit occurs
When a stock split occurs, the number of authorized shares remains unchanged, but the number of issued shares increases. This means that while the total number of shares a company can issue is limited by its articles of incorporation, the actual number of shares available to investors is increased. The difference between authorized and issued shares is crucial for understanding the company's capital structure and the impact of stock splits on shareholder equity.
FasterCapital
+2
just announced another what was it, $25 Mil to buy shares back?
Well it could te one of two things:
-the news of an increase in $s to buyback shares can lead to an
increase in the share price. So maybe the follow on announcement
of a major increase in the ATM (number of AUTHORIZED SHARES goes up)
amount that can be sold is supposed to offset the news of a buyback and even
make the shares cheaper to buy back. A WIN for the company IF they do a buyback.
And the ability to sell a lot more shares at an ATM can then do 2 things:
IF the share price runs up?
They can dilute at a much higher price (create fewer new shares to raise even more
cash)
and they can then raise the AUTHORIZED share count by up to $400 Mil worth of shares
sold. Could support a forward split.
I didn't realize till yesterday that the number of AUTHORIZED shares did NOT increase
in the same ratio of a split if one occurred. I could go into a deeper explanation, but
given this appears accurate? It appears that IF they are pondering a forward split for
instance, they likely need to increase the number of AUTHORIZED shares (which I believe
they just did with the upping to the $400 Mil mark).
Again, this is all premised on that I have been expecting them to due to the tight share count,
announce a forward split just to make more shares available to wall street. Like its been for
over a year now for those holding that long (or longer)? Have to wait and see where things go
vs what we anticipate based on our experiences/lessons learned.
Remains unchanged
Authorized shares when a stock aplit occurs
When a stock split occurs, the number of authorized shares remains unchanged, but the number of issued shares increases. This means that while the total number of shares a company can issue is limited by its articles of incorporation, the actual number of shares available to investors is increased. The difference between authorized and issued shares is crucial for understanding the company's capital structure and the impact of stock splits on shareholder equity.
FasterCapital
+2
Recent TNXP News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/31/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:28 AM
- Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 • GlobeNewswire Inc. • 03/23/2026 08:32:42 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 09:12:47 PM
- Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 • GlobeNewswire Inc. • 03/18/2026 08:58:49 PM
- Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 03/17/2026 08:35:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 10:01:04 AM
- Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/12/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 09:29:52 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 12:05:34 PM
- Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia • GlobeNewswire Inc. • 03/10/2026 12:00:00 PM
- Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting • GlobeNewswire Inc. • 03/09/2026 08:30:00 PM
- Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting • GlobeNewswire Inc. • 03/03/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 11:05:34 AM
- Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market • GlobeNewswire Inc. • 03/03/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:03:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:03:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:02:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 12:01:33 PM
